XOLAIR

Search results

Bio & Pharma Celltrion gets approval of Omlyclo in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...

Dec 09, 2024 (Gmt+09:00)
Bio & Pharma Celltrion applies for approval of Xolair biosimilar in Canada

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...

Dec 27, 2023 (Gmt+09:00)

Cookies on KED Global

We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.

Cookies on KED Global Sites

THE KOREA ECONOMIC DAILY, GLOBAL EDITION

SIGN IN
JOIN

Companies
Korean Investors
- Korean Investors Home
- Best Asset Managers by Korean Investors
Deals
- M&A
- ECM/DCM
Markets
Culture & Trends
Perspectives
Hidden Champions
Future Unicorns

Follow us

XOLAIR

Cookies on KED Global

No articles were found.Please search again.

No articles were found.
Please search again.